$0.73
2.12% today
Nasdaq, Nov 20, 07:13 pm CET
ISIN
US04545L1070
Symbol
ASRT

Assertio Therapeutics, Inc. Stock price

$0.75
-0.08 9.70% 1M
+0.04 5.36% 6M
-0.12 14.02% YTD
-0.23 23.17% 1Y
-2.08 73.53% 3Y
-0.76 50.36% 5Y
-76.81 99.03% 10Y
-20.13 96.41% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.00 0.19%
ISIN
US04545L1070
Symbol
ASRT
Industry

Key metrics

Basic
Market capitalization
$72.1m
Enterprise Value
$12.9m
Net debt
positive
Cash
$98.2m
Shares outstanding
96.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 0.6
EV/Sales
0.1 | 0.1
EV/FCF
0.7
P/B
0.8
Financial Health
Equity Ratio
42.5%
Return on Equity
-18.2%
ROCE
-22.3%
ROIC
-19.6%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$117.1m | $113.3m
EBITDA
$830.0k | $15.2m
EBIT
$-31.4m | $-35.8m
Net Income
$-42.9m | $-45.3m
Free Cash Flow
$17.6m
Growth (TTM | estimate)
Revenue
-11.4% | -9.3%
EBITDA
-91.8% | 97.4%
EBIT
-77.9% | -95.5%
Net Income
87.6% | -105.9%
Free Cash Flow
-23.9%
Margin (TTM | estimate)
Gross
67.9%
EBITDA
0.7% | 13.4%
EBIT
-26.8%
Net
-36.7% | -40.0%
Free Cash Flow
15.0%
More
EPS
$-0.5
FCF per Share
$0.2
Short interest
4.6%
Employees
58
Rev per Employee
$2.2m
Show more

Is Assertio Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Assertio Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Assertio Therapeutics, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Assertio Therapeutics, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Assertio Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
117 117
11% 11%
100%
- Direct Costs 38 38
4% 4%
33%
79 79
17% 17%
68%
- Selling and Administrative Expenses 77 77
5% 5%
66%
- Research and Development Expense 3.12 3.12
19% 19%
3%
0.83 0.83
92% 92%
1%
- Depreciation and Amortization 32 32
16% 16%
27%
EBIT (Operating Income) EBIT -31 -31
78% 78%
-27%
Net Profit -43 -43
88% 88%
-37%

In millions USD.

Don't miss a Thing! We will send you all news about Assertio Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Assertio Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
10 days ago
Assertio Holdings, Inc. ( ASRT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Mark L. Reisenauer - CEO & Director Paul Schwichtenberg - Executive VP & Chief Transformation Officer Ajay Patel - Executive VP & CFO Conference Call Participants Daniel Santos Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Div...
Neutral
Business Wire
10 days ago
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the third quarter ended September 30, 2025. Mark Reisenauer, Chief Executive Officer, stated: “In the third quarter ...
Neutral
GlobeNewsWire
23 days ago
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill.
More Assertio Therapeutics, Inc. News

Company Profile

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Head office United States
CEO Brendan O'Grady
Employees 58
Founded 1995
Website www.assertiotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today